搜索
Vyne Therapeutics Inc
VYNE添加自选
0.670USD
-0.000-0.07%
收盘 05/15, 16:00（美东）报价延迟15分钟
21.28M总市值
亏损市盈率 TTM
关于 Vyne Therapeutics Inc 公司
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Inc简介
公司代码VYNE
公司名称Vyne Therapeutics Inc
上市日期Jan 25, 2018
CEODomzalski (David)
员工数量13
证券类型Ordinary Share
年结日Jan 25
公司地址685 Route 202/206 N., Suite 301
城市BRIDGEWATER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编08807
电话18007757936
网址https://vynetherapeutics.com/
公司代码VYNE
上市日期Jan 25, 2018
CEODomzalski (David)
Vyne Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
100.91K
-3.97%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
55.23K
-7.25%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
47.05K
-6.11%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
100.91K
-3.97%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
55.23K
-7.25%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
47.05K
-6.11%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
收入明细
单位: USD更新时间: 4月6日 周一
单位: USD更新时间: 4月6日 周一
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
业务USD
名称
营收
占比
Royalty revenues
570.00K
0.00%
由于公司未披露，未能获取相关数据
业务
地区
业务USD
名称
营收
占比
Royalty revenues
570.00K
0.00%
股东统计
更新时间: 5月10日 周日
更新时间: 5月10日 周日
持股股东
股东类型
持股股东
持股股东
占比
Lynx1 Capital Advisors LLC
4.89%
Shay Capital LLC
4.87%
Anson Funds Management LP.
3.82%
Access Industries, Inc.
3.35%
Nantahala Capital Management, LLC
3.00%
其他
80.06%
持股股东
持股股东
占比
Lynx1 Capital Advisors LLC
4.89%
Shay Capital LLC
4.87%
Anson Funds Management LP.
3.82%
Access Industries, Inc.
3.35%
Nantahala Capital Management, LLC
3.00%
其他
80.06%
股东类型
持股股东
占比
Hedge Fund
17.05%
Investment Advisor
11.66%
Corporation
3.35%
Investment Advisor/Hedge Fund
3.07%
Individual Investor
1.29%
Research Firm
0.30%
Venture Capital
0.24%
其他
63.04%
机构持股
更新时间: 4月1日 周三
更新时间: 4月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2026Q1
92
11.08M
33.26%
-1.67M
2025Q4
88
4.87M
14.64%
-6.85M
2025Q3
84
8.51M
25.77%
-898.65K
2025Q2
84
9.46M
56.76%
-1.30M
2025Q1
81
9.36M
56.20%
-1.38M
2024Q4
92
9.37M
63.49%
-533.87K
2024Q3
88
8.98M
61.30%
-594.32K
2024Q2
89
9.65M
66.73%
+287.65K
2024Q1
92
9.64M
67.66%
+101.95K
2023Q4
101
10.22M
72.71%
+4.63M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Shay Capital LLC
1.62M
4.87%
+1.13M
+229.77%
Dec 31, 2025
Anson Funds Management LP.
1.27M
3.82%
+1.27M
--
Dec 31, 2025
Access Industries, Inc.
1.12M
3.35%
--
--
Dec 31, 2025
Nantahala Capital Management, LLC
1.00M
3%
+1.00M
--
Dec 31, 2025
T3 Companies, LLC
945.00K
2.84%
+945.00K
--
Dec 31, 2025
Delaware Street Capital, L.L.C.
696.47K
2.09%
--
--
Sep 30, 2024
Acadian Asset Management LLC
638.49K
1.92%
+192.08K
+43.03%
Dec 31, 2025
KVP Capital Advisors, LP
500.55K
1.5%
+500.55K
--
Dec 31, 2025
Two Sigma Investments, LP
383.10K
1.15%
+105.71K
+38.11%
Dec 31, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
公告日期
除权除息日
类型
比率
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 10, 2023
Merger
18→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
Feb 12, 2021
Merger
4→1
